Kriya Therapeutics develops scalable, off‑the‑shelf gene‑therapy vectors for ocular, metabolic, and neurological diseases, using a modular viral platform and validated promoters to enable tissue‑specific expression. Their approach reduces manufacturing complexity and cost, allowing rapid preclinical development and broader patient access to treatments for conditions such as type 1 diabetes, MASH, and trigeminal neuralgia.
Funding
$320.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OPSPIFounders
Product
Problem
Current gene therapy treatments are limited to a small patient population due to high manufacturing costs, complex delivery methods, and narrow therapeutic focus, leaving many individuals with serious genetic and metabolic diseases without viable options.
Solution
Kriya Therapeutics builds a versatile gene‑therapy platform that leverages validated biological pathways to create scalable, off‑the‑shelf vectors for multiple disease areas. By engineering delivery systems optimized for ocular, metabolic, and neurological targets, the company aims to reduce production complexity and cost while maintaining clinical efficacy. The platform supports rapid candidate selection and preclinical development, enabling progression from target identification to IND filing more efficiently. Kriya’s approach emphasizes broad patient access, seeking to bring transformative gene‑based treatments to the millions affected by conditions such as type 1 diabetes, metabolic liver disease (MASH), and trigeminal neuralgia.
Target Audience
Primary customers are pharmaceutical partners, academic research groups, and healthcare providers seeking gene‑therapy solutions for high‑prevalence metabolic, ophthalmic, and neurological disorders.
Features
- Modular viral vector architecture adaptable to ocular, hepatic, and central‑nervous‑system delivery
- Use of clinically validated promoters and regulatory elements to ensure tissue‑specific expression
- Scalable manufacturing process designed for high‑volume production and reduced per‑dose cost
- Integrated preclinical pipeline with biomarker‑driven go/no‑go decision points
- Proprietary bioinformatics tools for target pathway validation and vector optimization